Fatal Late-Onset Pneumocystis Pneumonia After Rituximab: Administration for Posttransplantation Recurrence of Focal Segmental Glomerulosclerosis—Case Report
| العنوان: | Fatal Late-Onset Pneumocystis Pneumonia After Rituximab: Administration for Posttransplantation Recurrence of Focal Segmental Glomerulosclerosis—Case Report |
|---|---|
| المؤلفون: | O. Kozińska-Przybył, M. Mikaszewska-Sokolewicz, D. Dęborska-Materkowska, Magdalena Durlik |
| المصدر: | Transplantation Proceedings. 46:2908-2911 |
| بيانات النشر: | Elsevier BV, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, medicine.medical_treatment, Pneumocystis pneumonia, Gastroenterology, Antibodies, Monoclonal, Murine-Derived, Immunocompromised Host, Young Adult, Fatal Outcome, Focal segmental glomerulosclerosis, Recurrence, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Immunologic Factors, Prospective Studies, Kidney transplantation, Immunosuppression Therapy, Transplantation, Glomerulosclerosis, Focal Segmental, business.industry, Pneumonia, Pneumocystis, Graft Survival, Immunosuppression, Plasmapheresis, medicine.disease, Kidney Transplantation, Surgery, Immunosuppressive drug, Kidney Failure, Chronic, Female, Rituximab, business, medicine.drug |
| الوصف: | Recurrence of focal segmental glomerulosclerosis (FSGS) is an important cause of graft loss after kidney transplantation. The management of patients with recurrent FSGS is not well established because there are no prospective randomized studies with a view to the impact of FSGS on graft survival. Recent studies suggest that rituximab, an anti-B-CD20 monoclonal antibody, may be a therapeutic alternative in selected cases resistant to conventional therapy. Opportunistic infections with rituximab have not been studied extensively, but recent studies suggest an increased risk for Pneumocystis jirovecii pneumonia (PJP) after rituximab therapy. We report the case of a kidney transplant recipient with recurrence of FSGS in the graft, in whom fatal PJP developed subsequent to treatment with rituximab. Our patient was treated with plasmapheresis and a complex immunosuppressive drug scheme for the recurrence of FSGS in transplanted kidney. However, this treatment had no effect on the amount of proteinuria, which increased to a maximum of 15 g/d after 18 session of plasmapheresis. Thereafter, 500 mg intravenously (IV) of rituximab was administered at 4-week intervals. The number of CD19-positive B lymphocytes decreased from 9% to 0.57%. Two months after the second dose of rituximab, proteinuria decreased to 2.1 g/d. Ten months after transplantation and 5 months after the first dose of rituximab was administered, severe PJP pneumonia developed and the patient died despite all efforts with antibiotic therapy. It seems essential that all renal transplant recipients treated with rituximab should currently be considered at an increased risk for PJP. This case suggests that prolonged or restarted prophylaxis for PJP should be recommended not only after conventional treatment for acute rejection episodes but also after use of rituximab in combination with other immunosuppressive therapy as well. |
| تدمد: | 0041-1345 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f98fefd6f1a0ec9e903ecba2a84f17eTest https://doi.org/10.1016/j.transproceed.2014.09.010Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....7f98fefd6f1a0ec9e903ecba2a84f17e |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....7f98fefd6f1a0ec9e903ecba2a84f17e 813 3 unknown 812.937194824219 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....7f98fefd6f1a0ec9e903ecba2a84f17e&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Fatal Late-Onset Pneumocystis Pneumonia After Rituximab: Administration for Posttransplantation Recurrence of Focal Segmental Glomerulosclerosis—Case Report
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22O%2E+Kozińska-Przybył%22">O. Kozińska-Przybył</searchLink><br /><searchLink fieldCode="AR" term="%22M%2E+Mikaszewska-Sokolewicz%22">M. Mikaszewska-Sokolewicz</searchLink><br /><searchLink fieldCode="AR" term="%22D%2E+Dęborska-Materkowska%22">D. Dęborska-Materkowska</searchLink><br /><searchLink fieldCode="AR" term="%22Magdalena+Durlik%22">Magdalena Durlik</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>Transplantation Proceedings</i>. 46:2908-2911 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Elsevier BV, 2014. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2014 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Ftreatment%22">medicine.medical_treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Pneumocystis+pneumonia%22">Pneumocystis pneumonia</searchLink><br /><searchLink fieldCode="DE" term="%22Gastroenterology%22">Gastroenterology</searchLink><br /><searchLink fieldCode="DE" term="%22Antibodies%2C+Monoclonal%2C+Murine-Derived%22">Antibodies, Monoclonal, Murine-Derived</searchLink><br /><searchLink fieldCode="DE" term="%22Immunocompromised+Host%22">Immunocompromised Host</searchLink><br /><searchLink fieldCode="DE" term="%22Young+Adult%22">Young Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Fatal+Outcome%22">Fatal Outcome</searchLink><br /><searchLink fieldCode="DE" term="%22Focal+segmental+glomerulosclerosis%22">Focal segmental glomerulosclerosis</searchLink><br /><searchLink fieldCode="DE" term="%22Recurrence%22">Recurrence</searchLink><br /><searchLink fieldCode="DE" term="%22hemic+and+lymphatic+diseases%22">hemic and lymphatic diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Immunologic+Factors%22">Immunologic Factors</searchLink><br /><searchLink fieldCode="DE" term="%22Prospective+Studies%22">Prospective Studies</searchLink><br /><searchLink fieldCode="DE" term="%22Kidney+transplantation%22">Kidney transplantation</searchLink><br /><searchLink fieldCode="DE" term="%22Immunosuppression+Therapy%22">Immunosuppression Therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Transplantation%22">Transplantation</searchLink><br /><searchLink fieldCode="DE" term="%22Glomerulosclerosis%2C+Focal+Segmental%22">Glomerulosclerosis, Focal Segmental</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Pneumonia%2C+Pneumocystis%22">Pneumonia, Pneumocystis</searchLink><br /><searchLink fieldCode="DE" term="%22Graft+Survival%22">Graft Survival</searchLink><br /><searchLink fieldCode="DE" term="%22Immunosuppression%22">Immunosuppression</searchLink><br /><searchLink fieldCode="DE" term="%22Plasmapheresis%22">Plasmapheresis</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Kidney+Transplantation%22">Kidney Transplantation</searchLink><br /><searchLink fieldCode="DE" term="%22Surgery%22">Surgery</searchLink><br /><searchLink fieldCode="DE" term="%22Immunosuppressive+drug%22">Immunosuppressive drug</searchLink><br /><searchLink fieldCode="DE" term="%22Kidney+Failure%2C+Chronic%22">Kidney Failure, Chronic</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Rituximab%22">Rituximab</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Recurrence of focal segmental glomerulosclerosis (FSGS) is an important cause of graft loss after kidney transplantation. The management of patients with recurrent FSGS is not well established because there are no prospective randomized studies with a view to the impact of FSGS on graft survival. Recent studies suggest that rituximab, an anti-B-CD20 monoclonal antibody, may be a therapeutic alternative in selected cases resistant to conventional therapy. Opportunistic infections with rituximab have not been studied extensively, but recent studies suggest an increased risk for Pneumocystis jirovecii pneumonia (PJP) after rituximab therapy. We report the case of a kidney transplant recipient with recurrence of FSGS in the graft, in whom fatal PJP developed subsequent to treatment with rituximab. Our patient was treated with plasmapheresis and a complex immunosuppressive drug scheme for the recurrence of FSGS in transplanted kidney. However, this treatment had no effect on the amount of proteinuria, which increased to a maximum of 15 g/d after 18 session of plasmapheresis. Thereafter, 500 mg intravenously (IV) of rituximab was administered at 4-week intervals. The number of CD19-positive B lymphocytes decreased from 9% to 0.57%. Two months after the second dose of rituximab, proteinuria decreased to 2.1 g/d. Ten months after transplantation and 5 months after the first dose of rituximab was administered, severe PJP pneumonia developed and the patient died despite all efforts with antibiotic therapy. It seems essential that all renal transplant recipients treated with rituximab should currently be considered at an increased risk for PJP. This case suggests that prolonged or restarted prophylaxis for PJP should be recommended not only after conventional treatment for acute rejection episodes but also after use of rituximab in combination with other immunosuppressive therapy as well. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 0041-1345 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f98fefd6f1a0ec9e903ecba2a84f17e" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f98fefd6f1a0ec9e903ecba2a84f17e</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1016/j.transproceed.2014.09.010" linkWindow="_blank">https://doi.org/10.1016/j.transproceed.2014.09.010</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => CLOSED ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....7f98fefd6f1a0ec9e903ecba2a84f17e ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 4
[StartPage] => 2908
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Male
[Type] => general
)
[1] => Array
(
[SubjectFull] => medicine.medical_specialty
[Type] => general
)
[2] => Array
(
[SubjectFull] => medicine.medical_treatment
[Type] => general
)
[3] => Array
(
[SubjectFull] => Pneumocystis pneumonia
[Type] => general
)
[4] => Array
(
[SubjectFull] => Gastroenterology
[Type] => general
)
[5] => Array
(
[SubjectFull] => Antibodies, Monoclonal, Murine-Derived
[Type] => general
)
[6] => Array
(
[SubjectFull] => Immunocompromised Host
[Type] => general
)
[7] => Array
(
[SubjectFull] => Young Adult
[Type] => general
)
[8] => Array
(
[SubjectFull] => Fatal Outcome
[Type] => general
)
[9] => Array
(
[SubjectFull] => Focal segmental glomerulosclerosis
[Type] => general
)
[10] => Array
(
[SubjectFull] => Recurrence
[Type] => general
)
[11] => Array
(
[SubjectFull] => hemic and lymphatic diseases
[Type] => general
)
[12] => Array
(
[SubjectFull] => Internal medicine
[Type] => general
)
[13] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[14] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[15] => Array
(
[SubjectFull] => Immunologic Factors
[Type] => general
)
[16] => Array
(
[SubjectFull] => Prospective Studies
[Type] => general
)
[17] => Array
(
[SubjectFull] => Kidney transplantation
[Type] => general
)
[18] => Array
(
[SubjectFull] => Immunosuppression Therapy
[Type] => general
)
[19] => Array
(
[SubjectFull] => Transplantation
[Type] => general
)
[20] => Array
(
[SubjectFull] => Glomerulosclerosis, Focal Segmental
[Type] => general
)
[21] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[22] => Array
(
[SubjectFull] => Pneumonia, Pneumocystis
[Type] => general
)
[23] => Array
(
[SubjectFull] => Graft Survival
[Type] => general
)
[24] => Array
(
[SubjectFull] => Immunosuppression
[Type] => general
)
[25] => Array
(
[SubjectFull] => Plasmapheresis
[Type] => general
)
[26] => Array
(
[SubjectFull] => medicine.disease
[Type] => general
)
[27] => Array
(
[SubjectFull] => Kidney Transplantation
[Type] => general
)
[28] => Array
(
[SubjectFull] => Surgery
[Type] => general
)
[29] => Array
(
[SubjectFull] => Immunosuppressive drug
[Type] => general
)
[30] => Array
(
[SubjectFull] => Kidney Failure, Chronic
[Type] => general
)
[31] => Array
(
[SubjectFull] => Female
[Type] => general
)
[32] => Array
(
[SubjectFull] => Rituximab
[Type] => general
)
[33] => Array
(
[SubjectFull] => business
[Type] => general
)
[34] => Array
(
[SubjectFull] => medicine.drug
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Fatal Late-Onset Pneumocystis Pneumonia After Rituximab: Administration for Posttransplantation Recurrence of Focal Segmental Glomerulosclerosis—Case Report
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => O. Kozińska-Przybył
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => M. Mikaszewska-Sokolewicz
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => D. Dęborska-Materkowska
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Magdalena Durlik
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 10
[Type] => published
[Y] => 2014
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 00411345
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsair
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 46
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Transplantation Proceedings
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |